Abstract:Aberrant activation of the canonical Wnt pathway due to accumulation of β-catenin occurs in approximately 70% of hepatocellular carcinomas (HCCs) and contributes to their initiation, development and progression. Genetic mutations in the components of this pathway account for only a subset of HCCs with β-catenin accumulation, suggesting that an alternative mechanism for Wnt/β-catenin activation is prevailing. Enhancer of zeste homolog 2 (EZH2) is known to promote tumorigenesis by down-regulating tumor-suppressor genes; however, whether EZH2 regulates oncogenic pathways is unclear. Using chromatin immunoprecipitation microarray, we uncovered 12 Wnt/β-catenin signal antagonists whose promoters were concordantly occupied by EZH2 and repressive histone modifications in hepatocellular HCC cells. EZH2 over-expressed in 42% (75/179) of human HCCs and significantly associated with β-catenin accumulation. Concomitant inhibition of EZH2 and histone deacetylase transcriptionally activated Wnt/β-catenin signal antagonists, suppressed T-cell factor-dependent transcriptional activity and down-regulated β-catenin transcriptional targets in HCC cells. Conversely, ectopic EZH2 over-expression in nontumorigenic hepatocytes increased cellular proliferation in a β-catenin-dependent manner and promoted tumorigenicity. This study uncovers an EZH2-mediated epigenetic mechanism that leads to Wnt/β-catenin signaling dyregulation in human HCC and suggests that therapeutic interventions targeting EZH2 may confer a clinical benefit in β-catenin-driven malignancies. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4881.

Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Supplementary Table 1 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis

Supplementary Table 7 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Supplementary Methods, Figures 1-4 from Rho Kinase Phosphorylation Promotes Ezrin-Mediated Metastasis in Hepatocellular Carcinoma

Polycomb Protein Ezh2 Activates Wnt/Beta-Catenin Signaling To Promote Hepatocellular Carcinoma Development

Supplementary Data from HBx-Induced HSPA8 Stimulates HBV Replication and Suppresses Ferroptosis to Support Liver Cancer Progression

Supplementary Figure 6 from E2F8 Contributes to Human Hepatocellular Carcinoma Via Regulating Cell Proliferation

Supplementary Figure 5 from E2F8 Contributes to Human Hepatocellular Carcinoma Via Regulating Cell Proliferation

Supplementary Tables 1-2 from E2F8 Contributes to Human Hepatocellular Carcinoma via Regulating Cell Proliferation

Supplementary Figure 4 from E2F8 Contributes to Human Hepatocellular Carcinoma Via Regulating Cell Proliferation

Supplementary Figure 3 from E2F8 Contributes to Human Hepatocellular Carcinoma via Regulating Cell Proliferation

Supplementary Figure 7 from E2F8 Contributes to Human Hepatocellular Carcinoma Via Regulating Cell Proliferation

Supplementary Figure Legends 1-7 from E2F8 Contributes to Human Hepatocellular Carcinoma Via Regulating Cell Proliferation

Supplementary Figure and Table Legends 1-4 from Combinatorial Pharmacologic Approaches Target EZH2-mediated Gene Repression in Breast Cancer Cells

Supplementary Figures and Methods from Canonical Wnt Signaling Remodels Lipid Metabolism in Zebrafish Hepatocytes Following Ras Oncogenic Insult

Supplementary Methods from AZ1366: an Inhibitor of Tankyrase and the Canonical Wnt Pathway That Limits the Persistence of Non–Small Cell Lung Cancer Cells Following EGFR Inhibition

Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinoma

Supplementary Figures 1-6, Tables 1-15, Methods from Epigenetic Silencing Mediated Through Activated PI3K/AKT Signaling in Breast Cancer

Supplementary Tables from A Feedback Circuitry Between Polycomb Signaling and Fructose-1, 6-Bisphosphatase Enables Hepatic and Renal Tumorigenesis